To evaluate the efficacy of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and their potential impact on survival outcomes.
Key Findings:
Median progression-free survival (PFS) was 4.21 months.
Median overall survival (OS) was 16.27 months.
1-year PFS rate was 43%, and 1-year OS rate was 80%.
Pooled objective response rate (ORR) was 45%, and disease control rate (DCR) was 65%.
Adverse events occurred in 90% of patients, with 34% experiencing grade 3 or higher events, indicating significant safety concerns.
Interpretation:
The findings suggest a potential improvement in ORR and DCR in recent studies, possibly due to refined patient selection and enhanced treatment strategies, although definitive conclusions require more high-quality evidence.
Limitations:
Predominance of single-arm studies.
Small sample sizes in several cohorts.
Heterogeneity across treatment regimens, dosing, and patient characteristics, which may affect the reliability of the results.
Conclusion:
The study enriches the existing evidence but highlights the need for robust, high-quality trials to draw definitive conclusions about the efficacy and safety of PD-1/PD-L1 inhibitors in NPC.
